Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis

Thrombosis and Haemostasis

Volumn 90, Issue 1, 2003, Pages 86-91

  Sartori, Maria Teresa ^a   Saggiorato, Graziella ^a   Pellati, Donatella ^a   Casonato, Alessandra ^a   Spiezia, Luca ^a   Pontara, Elena ^a   Gavasso, Sabrina ^a   Girolami, Antonio ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Ligneous conjunctivitis; Oral contraceptives; Plasminogen deficiency; Plasminogen gene mutations; Von Willebrand's disease

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTIGEN; ANTITHROMBIN; APC PROTEIN; BLOOD CLOTTING FACTOR 8; CONTRACEPTIVE AGENT; CYCLOSPORIN; D DIMER; DEXAMETHASONE; ESTROGEN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FIBRINOGEN; GESTAGEN; GLUTAMIC ACID; HYALURONIDASE; HYDROCORTISONE; LYSINE; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; RISTOCETIN; STEROID; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONJUNCTIVITIS; CONTROLLED STUDY; CORNEA TRANSPLANTATION; CUSHING DISEASE; DISEASE COURSE; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME SYNTHESIS; EXON; EYE; EYE SURGERY; EYELID RECONSTRUCTION; FAMILY; FEMALE; FEMALE FERTILITY; FIBRINOLYSIS; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPOPHYSECTOMY; HYPOPLASMINOGENEMIA; INTRON; LIGNEOUS CONJUNCTIVITIS; MALE; MUTATIONAL ANALYSIS; PEDIGREE; PILL; PREDICTION; PRIORITY JOURNAL; RNA SPLICING; VON WILLEBRAND DISEASE; WILD TYPE;

EID: 0037623679     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613603     Document Type: Article

References (34)

1. Cohen SR. Ligneous conjunctivitis: An ophthalmic disease with potentially fatal tracheobronchial obstruction. Laryngeal and tracheobronchial features. Ann Otol Rhinol Laryngol 1990; 99: 509-12.
2. Scurry J, et al. Ligeous (pseudomembranous) inflammation of the female genital tract. A report of two cases. J Reprod Med 1993; 38: 407-12.
3. Parunovic A, Stefanovic D. Conjunctivitis lignosa and hydrocephalus (an unusual association of 2 diseases). Vestn Oftalmol 1993; 109: 30-1.
4. Mingers AM, Heimburger N, Lutz E. Familiärer homozygoter und heterozygoter Typ I-Plasmonigenmangel. In: Scharrer I, Schramm W (eds). 25. Hämophilie-Symposium 1994. Springer, Berlin, 1995: 96-104.
5. Mingers AM, et al. Human homozygous type I plasminogen deficiency and ligneous conjunctivitis. APMIS 1999; 107: 62-72.
6. Ramsby ML, et al. Ligneous conjunctivitis: Biochemical evidence for hypofibrinolysis. Inflammation 2000; 24: 45-71.
7. Schuster V, et al. Homozygous mutations in the plasminogen gene of two unrelated girls with ligneous conjunctivitis. Blood 1997; 90: 958-66.
8. Schuster V, et al. Compound-heterozygous mutations in the plasminogen gene predispose to the development of ligneous conjunctivitis. Blood 1999; 93: 3457-66.
9. Schott D, et al. Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency. N Engl J Med 1998; 339: 1679-86.
10. Schuster V, et al. Homozygous and compound-heterozygous type I plasminogen deficiency is a common cause of ligneous conjunctivitis. Thromb Haemost 2001; 85: 1004-10.
11. Nussgens Z, Roggenkamper P. Ligneous conjunctivitis: Ten years follow-up. Ophthalmic Pediatr Genet 1993; 14: 137-40.
12. Schwartz GS, Holland EJ. Induction of ligneous conjunctivitis by conjunctival surgery. Am J Ophthalmol 1995; 120: 253-4.
13. Watts P, et al. Effective treatment of ligneous conjunctivitis with topical plasminogen. Am J Ophthalmol 2002; 133: 451-5.
14. Wright JG, et al. Fibrinolysis during normal human pregnancy: Complex inter-relationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time. Br J Haematol 1988; 69: 253-8.
15. Patrassi GM, et al. Further studies on the hypercoagulable state of patients with Cushing's syndrome. Thromb Haemost 1985; 54: 518-20.
16. Tait RC, Walzer I, Conie JA, et al. Plasminogen levels in healthy volunteers - Influence of age, sex, smoking and oral contraceptives. Thromb Haemost 1992; 68: 506-10.
17. Shigekiyo T, Tomonari A, Uno Y, Kishi Y. Danazol therapy in hypoplasminogenemia. Thromb Haemost 1992; 68: 233-4.
18. Mannucci PM, et al. Congenital plasminogen deficiency associated with venous thromboembolism: Therapeutic trial with stanozolol. Br J Haematol 1986; 63: 753-9.
19. Soria C, et al. Dosage dù plasminogène à l'aide d'un substrate chromogène tripeptidique. Pathol Biol 1976; 24: 725-29.
20. Laurell CB. Quantitative estimation of proteins by electrophoresis of human serum proteins. Annal Biochem 1966; 15: 45-52.
21. Casonato A, et al. Impaired release of tissue plasminogen activator (t-PA) following DDAVP infusion in von Willebrand's disease with low platelet and von Willebrand factor content. Blood Coagul Fibrinolysis 1992; 3: 149-53.
22. Casonato A, et al. The evaluation of factor VIII antigen by means of a simple slide test. Am J Clin Pathol 1985; 84: 107-11.
23. Girolami A, et al. A new congenital haemorrhagic condition due to the presence of abnormal factor X (factor X Friuli): Study of a large kindred. Br J Haematol 1970; 19: 179-92.
24. Friederich PW, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: Implication for prophylaxis. Ann Int Med 1996; 125: 955-60.
25. Simioni P, et al. Pseudohomozygous activated protein C resistance due to double heterozygous factor V defect (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: Report of two cases belonging to two unrelated kindreds. Thromb Haemost 1996; 75: 422-26.
26. Eriksson E, et al. Determination of plasminogen activator inhibitor in plasma using t-PA and chromogenic single point poly-D-lysine stimulated assay. Thromb Res 1988; 50: 91-101.
27. Declerck PJ, et al. Measurement of plasminogen activator inhibitor 1 in biological fluids with a murine monoclonal antibody-based enzyme-linked immunoassay. Blood 1988; 71: 220-25.
28. Holvoet P, et al. Assay of human tissue plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemost 1985; 54: 684-87.
29. Azuma H, et al. Congenital plasminogen deficiency caused by a Ser572 to Pro mutation. Blood 1993; 82: 475-80.
30. Petersen TE, et al. Characterization of the gene for human plasminogen, the key proenzyme in the fibrinolytic system. J Biol Chem 1990; 265: 6104-11.
31. Sartori MT, et al. Familial association of hypoplasminogenemia and heterozygous factor V deficiency. Clin Appl Thrombosis/Hemostasis 1999; 5: 277-81.
32. Sartori MT, et al. Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred. Clin Appl Thrombosis/Hemostasis 2000; 6: 36-40.
33. Manabe S, et al. Homozygous protein C deficiency combined with heterozygous dysplasminogenemia found in a 21-year-old thrombophilic male. Thromb Res 1985; 39: 333-41.
34. Mateo J, et al. Laboratory evaluation and clinical characteristics of 2132 consecutive unselected patients with venous thromboembolism - Results of the Spanish Multicentric Study on Thrombophilia (EMET Study). Thromb Haemost 1997; 77: 444-51.